US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
pharma · Osteopenia · Heat Stress · PTPI
Petros Pharmaceuticals
Petros Pharmaceuticals drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
New York, USA HQ
3 Employees
Public company Type
PTPI · NYSE Ticker
Company details
- Status
- Public
- HQ
- New York, USA
- Employees
- 3
- Programs
- 3
- Drugs
- 3
- Patents
- 0
Petros Pharmaceuticals pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Petros Pharmaceuticals drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Petros Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Petros Pharmaceuticals in public FDA and regional records.